<p>Versant Venture Management LLC 在第二季度收购了 Jade Biosciences, Inc.（NASDAQ:JBIO - 免费报告）的新股份，根据其最近向证券交易委员会的披露，该基金收购了 1,525,820 股公司股票，价值约为 15,243,000 美元。Jade Biosciences 占 Versant Venture Management LLC 投资组合的约 18.6%，使其成为该基金第三大持仓。Versant Venture Management LLC 在最近的报告期末持有 Jade Biosciences 约 181.43% 的股份。</p>
<p>其他一些机构投资者和对冲基金也增加或减少了对该公司的投资。新泽西州警察和消防员退休系统在第二季度以约 71,000 美元的价格购买了 Jade Biosciences 的新股份。Deltec Asset Management LLC 在第二季度以 157,000 美元的价格购买了 Jade Biosciences 的新股份。Intech Investment Management LLC 在第二季度以 230,000 美元的价格收购了 Jade Biosciences 的新股份。最后，Geode Capital Management LLC 在第二季度以 6,759,000 美元的价格购买了 Jade Biosciences 的新股份。</p>
<p>获取 <strong>Jade Biosciences</strong> 警报：</p>
<h2>Jade Biosciences 股票上涨 0.5%</h2>
<p>NASDAQ JBIO 的股票在周三开盘价为 12.65 美元。该公司的 50 日移动平均线为 9.11 美元。Jade Biosciences, Inc. 的 1 年低点为 6.57 美元，1 年高点为 100.10 美元。该公司的市值为 4.1277 亿美元，市盈率为 -1.13，贝塔值为 1.07。</p>
<p>Jade Biosciences（NASDAQ:JBIO - 获取免费报告）最近于 11 月 14 日（星期五）发布了其财报。公司报告本季度每股收益为（0.48）美元，超出市场共识预期的（0.57）美元，超出幅度为 0.09 美元。</p>
<h2>分析师设定新目标价</h2>
<p>多位分析师对该股票进行了评论。Weiss Ratings 在 10 月 31 日（星期五）的研究报告中重申了对 Jade Biosciences 股票的 &#34;卖出（e）&#34; 评级。Guggenheim 在周二的研究报告中将 Jade Biosciences 的目标价从 14.00 美元上调至 17.00 美元，并给予该股票 &#34;买入&#34; 评级。华尔街禅在周六的研究报告中将 Jade Biosciences 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。Wedbush 在 8 月 14 日（星期四）的研究报告中将 Jade Biosciences 的目标价从 17.00 美元上调至 18.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。最后，BTIG Research 在 10 月 9 日（星期四）的研究报告中开始覆盖 Jade Biosciences。他们对该股票给予了 &#34;买入&#34; 评级，并设定了 28.00 美元的目标价。四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Jade Biosciences 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 19.75 美元。</p>
<p><strong>查看我们最新的 JBIO 股票报告</strong></p>
<h2>Jade Biosciences 公司简介</h2>
<p>（免费报告）</p>
<p>Aerovate Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Jade Biosciences</li>
<li>三只可以提升您投资组合的家居改善股票</li>
<li>医疗保健轮换正在进行中：三只股票引领潮流</li>
<li>为什么投资高收益分红股票？</li>
<li>美敦力股票找到立足点——现在正在获得动能</li>
<li>增长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
</ul>
<p><strong>想看看其他对冲基金持有的 JBIO 吗？</strong> 访问 HoldingsChannel.com 获取 Jade Biosciences, Inc.（NASDAQ:JBIO - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkJJTw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Jade Biosciences 吗？</h2>
<p>在您考虑 Jade Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Jade Biosciences 并不在名单上。</p>
<p>虽然 Jade Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

JBIO

<p>Versant Venture Management LLC 投资了 1524 万美元于 Jade Biosciences，收购了 1,525,820 股，使其成为其投资组合中的重要部分。Jade Biosciences 的股票评级为适度买入，分析师设定了新的价格目标。该股票开盘价为 12.65 美元，市值为 4.1277 亿美元。分析师的评级各不相同，有些分析师上调了他们的价格目标。Jade Biosciences 专注于开发罕见心肺疾病的药物</p>

<p>Versant Venture Management LLC acquired a new position in Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) during the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund acquired 1,525,820 shares of the company's stock, valued at approximately $15,243,000. Jade Biosciences accounts for about 18.6% of Versant Venture Management LLC's portfolio, making the stock its 3rd biggest position. Versant Venture Management LLC owned about 181.43% of Jade Biosciences at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Versant Venture Management LLC 在第二季度收购了 Jade Biosciences, Inc.（NASDAQ:JBIO - 免费报告）的新股份，根据其最近向证券交易委员会的披露，该基金收购了 1,525,820 股公司股票，价值约为 15,243,000 美元。Jade Biosciences 占 Versant Venture Management LLC 投资组合的约 18.6%，使其成为该基金第三大持仓。Versant Venture Management LLC 在最近的报告期末持有 Jade Biosciences 约 181.43% 的股份。</p>
</div><p>A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Police &amp; Firemen s Retirement System of New Jersey bought a new position in Jade Biosciences during the 2nd quarter worth approximately $71,000. Deltec Asset Management LLC bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at $157,000. Intech Investment Management LLC acquired a new stake in shares of Jade Biosciences during the second quarter worth $230,000. Finally, Geode Capital Management LLC bought a new position in Jade Biosciences during the second quarter worth $6,759,000.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金也增加或减少了对该公司的投资。新泽西州警察和消防员退休系统在第二季度以约 71,000 美元的价格购买了 Jade Biosciences 的新股份。Deltec Asset Management LLC 在第二季度以 157,000 美元的价格购买了 Jade Biosciences 的新股份。Intech Investment Management LLC 在第二季度以 230,000 美元的价格收购了 Jade Biosciences 的新股份。最后，Geode Capital Management LLC 在第二季度以 6,759,000 美元的价格购买了 Jade Biosciences 的新股份。</p>
</div><p>Get <strong>Jade Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Jade Biosciences</strong> 警报：</p>
</div><h2>Jade Biosciences Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Jade Biosciences 股票上涨 0.5%</h2>
</div><p>Shares of NASDAQ JBIO opened at $12.65 on Wednesday. The firm's 50-day moving average is $9.11. Jade Biosciences, Inc. has a 1-year low of $6.57 and a 1-year high of $100.10. The firm has a market capitalization of $412.77 million, a price-to-earnings ratio of -1.13 and a beta of 1.07.</p>
<div class="lb-trans"><p>NASDAQ JBIO 的股票在周三开盘价为 12.65 美元。该公司的 50 日移动平均线为 9.11 美元。Jade Biosciences, Inc. 的 1 年低点为 6.57 美元，1 年高点为 100.10 美元。该公司的市值为 4.1277 亿美元，市盈率为 -1.13，贝塔值为 1.07。</p>
</div><p>Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.</p>
<div class="lb-trans"><p>Jade Biosciences（NASDAQ:JBIO - 获取免费报告）最近于 11 月 14 日（星期五）发布了其财报。公司报告本季度每股收益为（0.48）美元，超出市场共识预期的（0.57）美元，超出幅度为 0.09 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts have commented on the stock. Weiss Ratings reaffirmed a &#34;sell (e)&#34; rating on shares of Jade Biosciences in a research report on Friday, October 31st. Guggenheim lifted their price objective on Jade Biosciences from $14.00 to $17.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Wall Street Zen upgraded Jade Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Wedbush raised their target price on Jade Biosciences from $17.00 to $18.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, August 14th. Finally, BTIG Research began coverage on Jade Biosciences in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $28.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Jade Biosciences presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $19.75.</p>
<div class="lb-trans"><p>多位分析师对该股票进行了评论。Weiss Ratings 在 10 月 31 日（星期五）的研究报告中重申了对 Jade Biosciences 股票的 &#34;卖出（e）&#34; 评级。Guggenheim 在周二的研究报告中将 Jade Biosciences 的目标价从 14.00 美元上调至 17.00 美元，并给予该股票 &#34;买入&#34; 评级。华尔街禅在周六的研究报告中将 Jade Biosciences 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。Wedbush 在 8 月 14 日（星期四）的研究报告中将 Jade Biosciences 的目标价从 17.00 美元上调至 18.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。最后，BTIG Research 在 10 月 9 日（星期四）的研究报告中开始覆盖 Jade Biosciences。他们对该股票给予了 &#34;买入&#34; 评级，并设定了 28.00 美元的目标价。四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Jade Biosciences 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 19.75 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on JBIO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 JBIO 股票报告</strong></p>
</div><h2>Jade Biosciences Profile</h2>
<div class="lb-trans"><h2>Jade Biosciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Jade Biosciences</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Jade Biosciences</li>
<li>三只可以提升您投资组合的家居改善股票</li>
<li>医疗保健轮换正在进行中：三只股票引领潮流</li>
<li>为什么投资高收益分红股票？</li>
<li>美敦力股票找到立足点——现在正在获得动能</li>
<li>增长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JBIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 JBIO 吗？</strong> 访问 HoldingsChannel.com 获取 Jade Biosciences, Inc.（NASDAQ:JBIO - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkJJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Jade Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Jade Biosciences 吗？</h2>
</div><p>Before you consider Jade Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Jade Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jade Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Jade Biosciences 并不在名单上。</p>
</div><p>While Jade Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Jade Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Versant Venture Management LLC 向 Jade Biosciences, Inc. $JBIO 投资了 1524 万美元